Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 4,090 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Obstructive Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Not applicable Interventional Results available

Sustainability of Pulmonary Rehab Gains

NCT02241733
View directory record Official record
Conditions
COPD
Interventions
Breathing retraining plus exercise, Exercise only
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 17, 2026, 6:10 AM EDT
Completed No phase listed Observational

Adiposity and Airway Inflammation in HIV-Associated Airway Disease

NCT02975258
View directory record Official record
Conditions
Asthma, HIV, Adiposity
Interventions
Blood draw, Questionnaires, Spirometry, Methacholine challenge test, Quantitative CT scans, Urine pregnancy test, Adipose biopsy, Exhaled nitric oxide measurement
Procedure · Other · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 17, 2026, 6:10 AM EDT
Withdrawn Not applicable Interventional

Airway Ultrasound Prediction and Correlation

NCT03313947
View directory record Official record
Conditions
Obstructive Sleep Apnea, Difficult Airway
Interventions
Ultrasound, Questionnaire
Procedure · Other
Lead sponsor
Vidya Raman
Other
Eligibility
3 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 17, 2026, 6:10 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Inhaled Steroids on Gene Expression in the Lungs - 2

NCT00826748
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Beclomethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

NCT05165485
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Revefenacin, Tiotropium, Revefenacin Placebo, Tiotropium Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
76
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxidative Stress in Asthma

NCT04512547
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Hyperpolarized 129XeMRI
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD6793, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Recruiting Not applicable Interventional

Resources and Education for Addressing Chronic Health (REACH)

NCT07819747
View directory record Official record
Conditions
Asthma (Diagnosis)
Interventions
REACH
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years to 18 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Results available

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

NCT03890666
View directory record Official record
Conditions
Asthma
Interventions
Albuterol eMDPI DS, albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

School Inner-City Asthma Intervention Study (SICAS-2)

NCT02291302
View directory record Official record
Conditions
Asthma
Interventions
integrated pest management, air purifier, No intervention (control)
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 15 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Not applicable Interventional

A Pilot Stress Management Intervention Study for High Risk Children With Asthma

NCT02091648
View directory record Official record
Conditions
Asthma
Interventions
I Can Cope Intervention, Standard Education Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 14 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 17, 2026, 6:10 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04669743
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
Interventions
Ozone exposure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

NCT05326412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Itepekimab SAR440340
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Torrance, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Results available

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02109172
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

NCT00670930
View directory record Official record
Conditions
Allergic Asthma
Interventions
omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Not applicable Interventional Results available

Peak Inspiratory Flow Rates in Patients With COPD

NCT04168775
View directory record Official record
Conditions
COPD
Interventions
Home PIFR monitoring with InCheck Dial
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 17, 2026, 6:10 AM EDT
Active, not recruiting No phase listed Observational

Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care

NCT07568119
View directory record Official record
Conditions
Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Airway clearance therapy through acoustic oscillations
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
11 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 17, 2026, 6:10 AM EDT
Enrolling by invitation Phase 3 Interventional

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

NCT02796937
View directory record Official record
Conditions
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Interventions
Alpha-1 MP
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
20 Years to 72 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Miami, Florida • Wilmington, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 17, 2026, 6:10 AM EDT
Completed No phase listed Observational

To Evaluate the Use of ASTHMA IQ in a Primary Care Setting

NCT01296477
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
American Academy of Family Physicians
Other
Eligibility
12 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 17, 2026, 6:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Response to Rhinovirus Challenge

NCT02910401
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Rhinovirus (GMP RV16 HRV-16)
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 17, 2026, 6:10 AM EDT
Recruiting Phase 2 Interventional

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

NCT03762395
View directory record Official record
Conditions
Asthma, Obesity
Interventions
CXA-10, Matching Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 17, 2026, 6:10 AM EDT